

Supplementary Table 15: Patient information for Supplementary Figure 9

		CD	UC
<b>Number</b>		5	6
<b>Age (Ø, range)</b>		35 (25-60)	38 (25-44)
<b>Female [%]</b>		40.0	66.7
<b>HBI (Ø, range)</b>		2.8 (0-7)	
<b>Mayo c.s. (Ø, range)</b>			1.3 (0-2)
<b>Therapy [%]</b>	<i>Aminosalisylates</i>	20.0	100.0
	<i>Steroids</i>	40.0	33.3
	<i>Immunosuppressants</i>	0.0	0.0
	<i>Anti-TNF antibodies</i>	80.0	66.7
	<i>Vedolizumab</i>	0.0	0.0
	<i>Ustekinumab</i>	20.0	33.3
<b>Disease localization [%]</b>		L1: 40.0	E1: 16.7
		L2: 0.0	E2: 0.0
		L3: 20.0	E3: 83.3
		L4: 0.0	
		L4+: 40.0	